Japanese Encephalitis
A mosquito-borne viral infection found mainly in Asia and the western Pacific that rarely causes brain inflammation but can be fatal or disabling when it does.
What causes Japanese Encephalitis?
Japanese encephalitis is caused by Japanese encephalitis virus, a flavivirus transmitted by infected Culex mosquitoes. The virus cycles mainly between mosquitoes, pigs, and wading birds; humans are usually dead-end hosts.
Symptoms and what to notice
Most infections cause no symptoms. Mild illness may include fever and headache. Severe disease can cause high fever, severe headache, vomiting, stiff neck, confusion, seizures, weakness, movement disorders, coma, and encephalitis.
How long can it last?
Symptoms usually begin 5 to 15 days after an infected mosquito bite. Severe illness requires hospitalization and recovery can take weeks or months. Neurological, cognitive, behavioral, or movement problems may persist permanently.
How serious is Japanese Encephalitis?
Fewer than 1% of infections cause encephalitis, but about 20% to 30% of encephalitis cases are fatal and 30% to 50% of survivors have significant neurological or psychiatric aftereffects.
Treatment and management
There is no Japanese encephalitis-specific antiviral. Treatment is supportive and may include airway protection, seizure treatment, management of intracranial pressure, fluids, fever control, rehabilitation, and intensive care.
Vaccine: who and when?
Product: IXIARO is the only Japanese encephalitis vaccine available in the United States. It is approved from age 2 months. The primary series is two doses 28 days apart; adults ages 18-65 may receive dose two 7-28 days after dose one. The final dose should be at least one week before travel. A booster is recommended after at least one year when exposure risk continues.
Cost note: IXIARO and travel-clinic fees vary and may not be covered by insurance. Travelers should request a complete current estimate for the two-dose series and any consultation or administration charges.
Trusted source
Patient cost varies by insurance, provider, location, and eligibility. Coverage and public-health access differ, so listed prices are examples rather than guaranteed patient prices. This page is for general education and does not replace individualized medical advice, diagnosis, vaccination assessment, or treatment.
Japanese Encephalitis: Symptoms, Causes, Treatment, Prevention, and Vaccine Information
Japanese encephalitis virus is a leading vaccine-preventable cause of viral encephalitis in Asia. Infection risk for most short-term urban travelers is very low, yet a single severe case can be catastrophic. Risk rises with long stays, rural or agricultural exposure, extensive nighttime outdoor activity, monsoon-season travel, and uncertain itineraries. Vaccination decisions therefore depend on destination, season, duration, accommodations, and activity rather than country name alone.
Important: This page is for general education. It does not replace diagnosis, treatment, vaccination advice, or emergency care from a qualified healthcare professional.
Quick Facts
| Topic | Current information |
|---|---|
| Cause | Japanese encephalitis is caused by Japanese encephalitis virus, a flavivirus transmitted by infected Culex mosquitoes. The virus cycles mainly between mosquitoes, pigs, and wading birds; humans are usually dead-end hosts. |
| Main symptoms | Most infections cause no symptoms. Mild illness may include fever and headache. Severe disease can cause high fever, severe headache, vomiting, stiff neck, confusion, seizures, weakness, movement disorders, coma, and encephalitis. |
| Typical course | Symptoms usually begin 5 to 15 days after an infected mosquito bite. Severe illness requires hospitalization and recovery can take weeks or months. Neurological, cognitive, behavioral, or movement problems may persist permanently. |
| Treatment | There is no Japanese encephalitis-specific antiviral. Treatment is supportive and may include airway protection, seizure treatment, management of intracranial pressure, fluids, fever control, rehabilitation, and intensive care. |
| Vaccine status | Product: IXIARO is the only Japanese encephalitis vaccine available in the United States. It is approved from age 2 months. The primary series is two doses 28 days apart; adults ages 18-65 may receive dose two 7-28 days after dose one. The final dose should be at least one week before travel. A booster is recommended after at least one year when exposure risk continues. |
History and Public-Health Importance
Large epidemics of encephalitis were recognized in Japan in the late nineteenth and early twentieth centuries. The virus was isolated in the 1930s, and vaccination later transformed disease burden in countries with routine programs. Transmission persists across much of Asia and parts of the western Pacific because mosquitoes, pigs, and birds maintain the cycle. Human vaccination and mosquito control reduce disease but cannot eradicate the environmental reservoir.
What Causes Japanese Encephalitis?
Japanese encephalitis is caused by Japanese encephalitis virus, a flavivirus transmitted by infected Culex mosquitoes. The virus cycles mainly between mosquitoes, pigs, and wading birds; humans are usually dead-end hosts.
Culex mosquitoes usually become infected after feeding on pigs or wading birds and transmit virus during later bites. Humans do not develop enough virus in blood to infect ordinary mosquitoes and do not spread disease through casual contact, coughing, or touching. Transmission often peaks during warm or rainy periods in temperate regions and may occur year-round in tropical areas.
Symptoms and Typical Course
Most infections cause no symptoms. Mild illness may include fever and headache. Severe disease can cause high fever, severe headache, vomiting, stiff neck, confusion, seizures, weakness, movement disorders, coma, and encephalitis.
Most infections are silent. Severe illness often begins with fever, headache, vomiting, and altered mental status, followed by seizures, paralysis, tremor, abnormal movements, or coma. Children may present with irritability or seizures. The acute phase can progress rapidly, and survivors may need prolonged physical, speech, cognitive, or behavioral rehabilitation.
Complications and Who Is at Higher Risk
Fewer than 1% of infections cause encephalitis, but about 20% to 30% of encephalitis cases are fatal and 30% to 50% of survivors have significant neurological or psychiatric aftereffects.
Brain swelling, seizures, aspiration, respiratory failure, and autonomic instability can be fatal. Survivors may have weakness, movement disorders, speech impairment, learning problems, memory loss, emotional changes, or recurrent seizures. Children with severe disease can experience lifelong developmental effects.
How It Is Diagnosed
Diagnosis usually relies on Japanese encephalitis virus IgM antibody in cerebrospinal fluid or serum, interpreted with symptoms, travel, vaccination history, and timing. Cross-reactivity with other flaviviruses can complicate serology. Brain imaging and spinal-fluid studies help assess encephalitis and exclude other causes but are not individually specific.
Treatment and Recovery
There is no Japanese encephalitis-specific antiviral. Treatment is supportive and may include airway protection, seizure treatment, management of intracranial pressure, fluids, fever control, rehabilitation, and intensive care.
No antiviral has proven to eliminate the virus. Hospital care focuses on airway and breathing, seizures, intracranial pressure, fluids, electrolyte balance, fever, nutrition, and prevention of secondary complications. Rehabilitation begins as soon as the patient is stable. Patients should not donate blood for four months after illness under CDC guidance.
Vaccine Information
Product: IXIARO is the only Japanese encephalitis vaccine available in the United States. It is approved from age 2 months. The primary series is two doses 28 days apart; adults ages 18-65 may receive dose two 7-28 days after dose one. The final dose should be at least one week before travel. A booster is recommended after at least one year when exposure risk continues.
IXIARO is an inactivated, Vero-cell-derived vaccine. Two doses are required before initial exposure; one dose is not considered a complete primary series. Children ages 2 months through 2 years receive a smaller volume than older recipients. CDC recommends vaccination for people moving to an endemic area, travelers spending a month or more in risk areas, frequent travelers, and selected shorter-term travelers with substantial rural or outdoor exposure. It is not routinely recommended for very short urban trips with minimal risk.
Prevention
Use IXIARO when indicated, apply EPA-registered insect repellent, wear long sleeves and pants, treat clothing and gear with permethrin, sleep in screened or air-conditioned rooms, and use bed nets where needed. Mosquitoes that spread JE often bite from dusk through dawn, so nighttime protection is especially important.
When to Seek Medical Care
Seek emergency care for fever with severe headache, confusion, seizures, weakness, or altered consciousness during or after travel in a risk area. Tell clinicians the exact destinations, dates, rural activities, and vaccination history.
Frequently Asked Questions
Is Japanese encephalitis contagious between people?
No. It is acquired from infected mosquitoes; ordinary person-to-person transmission does not occur.
Who should consider IXIARO?
Long-term or frequent travelers and selected shorter-term travelers with meaningful rural, agricultural, or nighttime outdoor exposure.
How many IXIARO doses are needed?
Two for the primary series. Adults ages 18-65 may use an accelerated interval; the final dose must be at least one week before travel.
Is a booster needed?
Yes, when the primary series was completed at least a year earlier and exposure risk continues or will recur.
Key Takeaway
Japanese encephalitis is rare in travelers but devastating when severe. A destination-specific risk assessment, complete IXIARO series, and meticulous mosquito-bite prevention offer the best protection.
Medical, treatment, and vaccine information was reviewed against official U.S. public-health guidance available through September 2026.